GCG and Alzheimer disease: Several studies have shown that GLP-1 and GLP-1 analogues may delay cognitive decline in models of AD and Parkinson’s disease as well as to mediate neuroprotection in in vitro and in vivo models of diabetes and stroke [48, 51, 75].